Tesamorelin

Description

Tesamorelin Reference Material | Stabilized GHRH Analog

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid N-terminal modification that increases plasma stability. It is the only FDA-approved GHRH analog (Egrifta®), providing researchers with a compound supported by extensive clinical pharmacokinetic characterization.

Pharmacological Profile

Tesamorelin binds GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion while preserving hypothalamic-pituitary feedback regulation. Its extended plasma stability compared to native GHRH makes it a practical reference ligand for sustained somatotroph stimulation paradigms in preclinical models.

Laboratory Research Applications

• GHRH receptor binding kinetics and somatotroph cAMP signaling
• GH/IGF-1 axis modulation in preclinical models
• Visceral adipose tissue biology and lipid metabolism studies
• Metabolic parameter research (lipid profiles, glucose regulation)
• Cognitive function research — published literature on mild cognitive impairment models
• Combination GH secretagogue studies (paired with GHSR-1a agonists)

Specifications

• Molecular Weight: 5,135.77 g/mol
• Form: Lyophilized powder
• Purity: ≥98% (HPLC verified)
• Storage: 2–8°C; -20°C long-term

For laboratory research use only. Not for human or veterinary use.